Sacchetti, Cristiano
Bai, Yunpeng
Stanford, Stephanie M.
Di Benedetto, Paola
Cipriani, Paola
Santelli, Eugenio
Piera-Velazquez, Sonsoles
Chernitskiy, Vladimir
Kiosses, William B.
Ceponis, Arnold
Kaestner, Klaus H.
Boin, Francesco
Jimenez, Sergio A.
Giacomelli, Roberto
Zhang, Zhong-Yin
Bottini, Nunzio
Article History
Received: 1 June 2016
Accepted: 23 August 2017
First Online: 20 October 2017
Competing interests
: This work was supported in part by investigator-initiated grants from Kyowa Kirin Pharmaceutical Research Inc. (formerly Kyowa Hakko Kirin California Inc.) to N.B. and from Illumina Inc. to C.S. The La Jolla Institute for Allergy and Immunology holds a pending patent application, “PTP4A1 as a therapeutic target for fibrotic diseases and disorders including systemic sclerosis”, with N.B., C.S. and S.M.S. named as inventors. The remaining authors declare no competing financial interests.